Evolus, Inc. filings document financial results and corporate disclosures for a Nasdaq-listed performance beauty company focused on aesthetic injectables. Its 8-K reports furnish quarterly and preliminary results, disclose capital-structure actions such as the termination of an at-the-market sales agreement, and record financing arrangements including a senior secured asset-based revolving credit facility.
The company’s proxy and current reports also cover governance and compensation matters, including a classified board structure, director reclassification, officer appointments and departures, equity award plans, executive compensation, shareholder meeting proposals, and related-party disclosures tied to its public-company reporting obligations.
Evolus, Inc. is a global performance beauty company focused on cash-pay medical aesthetics, selling the neurotoxin Jeuveau and a line of injectable HA gels branded Evolysse. Jeuveau is approved for frown lines in multiple markets, while Evolysse Form and Smooth were approved in the United States in 2025 for wrinkles and folds.
The company targets growth in large neurotoxin and dermal filler segments but continues to post losses, with a $51.6 million net loss in 2025 and an accumulated deficit of $661.0 million. Evolus depends heavily on manufacturing and licensing partners Daewoong and Symatese, and pays Medytox royalties on Jeuveau sales, which reduces profitability.
Evolus highlights competitive pressures from larger players, regulatory and trade risks, reliance on consumer discretionary spending, and the need for additional financing if assumptions prove incorrect. As of the last reported figures, the company had an approximate market value of $560.4 million and 334 employees across the United States, Canada, Europe and Australia.
Evolus, Inc. entered a new senior secured, asset-based revolving credit facility of up to $30.0 million with Eclipse Business Capital, maturing on March 3, 2029, with an uncommitted $10.0 million accordion and a $10.0 million minimum utilization requirement.
Borrowings price at adjusted term SOFR (floor 2.0%) plus a 4.25% margin, with closing fees of 1.0% and prepayment fees starting at 3.0% and stepping down over two years. The facility is secured by substantially all company assets and includes covenants on minimum excess availability and capital expenditures.
For 2025, Evolus generated total net revenue of $297.2 million, up 12%, with Q4 revenue of $90.3 million and Q4 GAAP operating income of $4.2 million. Full-year GAAP loss from operations was $32.7 million and net loss was $51.6 million, while non-GAAP operating loss was $9.4 million. The company ended 2025 with cash of $53.8 million and total liabilities of $249.0 million, resulting in a stockholders’ deficit of $23.1 million.
Evolus projects 2026 revenue of $327–$337 million (growth of 10–13%), adjusted gross margin of 65.5–67.0% and non-GAAP operating expenses of $210–$216 million, aiming for a low- to mid-single digit Adjusted EBITDA margin in 2026 and 13–15% Adjusted EBITDA margins on $450–$500 million revenue by 2028.
Parschauer Karah Herdman reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Karah Herdman Parschauer reported an equity compensation grant in the form of restricted stock units (RSUs). The filing shows an award of 45,559 shares of common stock at a price of $0.00 per share, bringing her directly owned total to 77,742 shares.
According to the disclosure, these 45,559 RSUs each represent a contingent right to receive one share of Evolus common stock. The RSUs are scheduled to vest in full on the one year anniversary of February 17, 2026, if she remains in continuous service through the vesting date, with potential accelerated vesting in certain change-of-control and other specified events.
Stewart Brady reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Stewart Brady reported receiving a grant of 45,559 shares of common stock in the form of restricted stock units (RSUs). The award was priced at $0.00 per share, increasing his directly held common stock (including RSUs) to 134,188 shares after the transaction.
Each RSU represents a contingent right to receive one Evolus common share. The RSUs will vest in full on the one-year anniversary of February 17, 2026, if Brady remains in continuous service through the vesting date, with potential accelerated vesting upon certain changes of control of the company.
Evolus, Inc. Chief Financial Officer Tatjana Mitchell reported equity awards on Form 4. She acquired 121,489 performance restricted stock units, 177,471 stock options, and 121,489 shares of common stock at a grant price of $0.00 per share, all held directly.
The restricted stock units vest in four equal annual installments starting on February 17, 2026, with potential acceleration upon certain terminations or a change in control. The performance-based units can deliver up to 200% of the granted amount based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028. The stock options also vest in four equal annual installments beginning on February 17, 2026, subject to continued service and similar acceleration conditions.
White Albert G III reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Albert G. White III received an equity award of 45,559 shares of common stock in the form of restricted stock units (RSUs) on February 17, 2026. The award was granted at no cash cost per share and is a stock-based compensation grant, not an open-market purchase.
Each RSU represents a contingent right to receive one Evolus common share and will vest in full on “the one year anniversary of February 17, 2026,” if he remains in continuous service, with potential accelerated vesting upon certain changes of control. Following this grant, his reported direct holdings total 95,937 shares of common stock.
MOATAZEDI DAVID reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director and officer David Moatazedi reported equity awards on February 17, 2026. He was granted 626,424 performance-based restricted stock units, where each unit can deliver up to 200% of a target share amount based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028. He also received 313,212 time-based restricted stock units and 457,541 stock options, each vesting in four equal annual installments starting on February 17, 2026, subject to continued service and potential acceleration in certain circumstances.
Malik Vikram reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Vikram Malik reported an equity award of 45,559 shares of common stock in the form of restricted stock units (RSUs). Each RSU represents the right to receive one share of Evolus common stock for no cash payment.
The RSUs will vest in full on the one year anniversary of February 17, 2026, as long as Malik remains in continuous service, with accelerated vesting possible in certain change-of-control or similar events. After this grant, Malik beneficially owns 321,109 shares of Evolus common stock.
Avelar Rui reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. reported that company officer Rui Avelar received new equity awards on February 17, 2026. Grants included 94,913 performance-based restricted stock units, 94,913 time-based restricted stock units payable in common stock, and stock options for 138,649 shares at no cost on grant.
The time-based RSUs and options vest in four equal annual installments starting February 17, 2026, subject to continued service and possible acceleration in certain circumstances. The performance-based units can deliver up to 200% of the granted PSUs based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028.
GILL DAVID N reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director David N. Gill received a grant of 45,559 restricted stock units (RSUs) of common stock. The award was made at no cash cost per share and will vest in full on the one-year anniversary of February 17, 2026, if he remains in continuous service. Following this grant, Gill directly holds 86,887 shares or share-equivalent RSUs.